南方医科大学学报

南方医科大学学报 ›› 2022, Vol. 42 ›› Issue (5): 718-723.doi: 10.12122/j.issn.1673-4254.2022.05.13

• • 上一篇    下一篇

丹参酮IIA通过介导PI3K/Akt-eNOS信号通路改善野百合碱所致大鼠肺动脉高压

张喜民，刘思佳，孙亚彬，李国锋   

  1. 南方医科大学南方医院药学部，合理用药评价与药物递送发展实验室，广东 广州 510515；南方医科大学药学院广东省新药筛选重点实验室，广东 广州 510515；广州民航职业技术学院，广东 广州 510403；广州白云山和记黄埔中药有限公司，广东 广州 510515
  • 出版日期:2022-05-20 发布日期:2022-06-02

Tanshinone IIA alleviates monocrotaline-induced pulmonary hypertension in rats through the PI3K/Akt-eNOS signaling pathway

ZHANG Ximin, LIU Sijia, SUN Yabin, LI Guofeng   

  1. Department of Pharmacy, Rational Medication Evaluation and Drug Delivery Technology Lab, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China; Guangzhou Civil Aviation College, Guangzhou 510403, China; Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Co., Ltd, Guangzhou 510515, China
  • Online:2022-05-20 Published:2022-06-02

RichHTML

25

PDF

485

摘要： 目的 探究丹参酮IIA治疗野百合碱所致大鼠肺动脉高压（PAH）的作用机制。方法 选取100只SD雄性大鼠，按随机数字表法分为5组（20只/组）：模型组（MCT）、丹参酮IIA组（TIIA）、丹参酮IIA+PI3K抑制剂组（TP）、PI3K抑制剂组（PI）、对照组。除对照组颈背部注射等体积生理盐水外，剩余大鼠均颈背部注射野百合碱（MCT）诱导肺动脉高压模型。2周后，丹参酮IIA组腹腔注射丹参酮IIA10 mg/kg进行治疗，丹参酮IIA+PI3K抑制剂组注射丹参酮IIA10 mg/kg+PI3K抑制剂1 mg/kg，PI3K抑制剂组注射PI3K抑制剂1 mg/kg，对照组和模型组均腹腔注射等体积生理盐水。治疗2周后，采用苏木精-伊红（HE）染色实验和α-SMA免疫荧光染色实验评估大鼠肺血管形态；Western blot实验评估大鼠肺组织中磷脂酰肌醇3激酶（PI3K）、蛋白激酶B（PKB/Akt）、内皮型一氧化氮合酶（eNOS）的磷酸化水平；ELISA法测定eNOS、NO水平。结果 HE染色实验和α-SMA免疫荧光染色证实丹参酮IIA能有效抑制PAH大鼠肺血管中膜厚度和血管肌化水平（P<0.01）；Western blot实验结果显示丹参酮IIA能够显著提高PAH大鼠肺组织中PI3K、Akt和eNOS蛋白的磷酸化水平；ELISA 实验结果显示模型组eNOS、NO水平降低（P<0.01）。结论 丹参酮IIA能够通过介导PI3K/Akt-eNOS信号通路改善野百合碱所致大鼠肺动脉高压。

关键词: 肺动脉高压；PI3K/Akt-eNOS；丹参酮IIA；野百合碱；信号通路

Abstract: Objective To explore the therapeutic mechanism of tanshinone IIA in the treatment of pulmonary arterial hypertension (PAH) in rats. Methods A total of 100 male SD rats were randomized into 5 groups (n=20), and except for those in the control group with saline injection, all the rats were injected with monocrotaline (MCT) on the back of the neck to establish models of pulmonary hypertension. Two weeks after the injection, the rat models received intraperitoneal injections of tanshinone IIA (10 mg/kg), phosphatidylinositol 3 kinase (PI3K) inhibitor (1 mg/kg), both tanshinone IIA and PI3K inhibitor, or saline (model group) on a daily basis. After 2 weeks of treatment, HE staining and α-SMA immunofluorescence staining were used to evaluate the morphology of the pulmonary vessels of the rats. The phosphorylation levels of PI3K, protein kinase B (PKB/Akt) and endothelial nitric oxide synthase (eNOS) in the lung tissue were determined with Western blotting; the levels ofeNOS and NO were measured using enzyme-linked immunosorbent assay (ELISA). Results The results of HE staining and α-SMA immunofluorescence staining showed that tanshinone IIA effectively inhibited MCT-induced pulmonary artery intima-media thickening and muscularization of the pulmonary arterioles (P<0.01). The results of Western blotting showed that treatment with tanshinone IIA significantly increased the phosphorylation levels of PI3K, Akt and eNOS proteins in the lung tissue of PAH rats; ELISA results showed that the levels of eNOS and NO were significantly decreased in the rat models after tanshinone IIA treatment (P<0.01). Conclusion Treatment with tanshinone IIA can improve MCT-induced pulmonary hypertension in rats through the PI3K/Akt-eNOS signaling pathway.

Key words: pulmonary hypertension; PI3K/Akt-eNOS; tanshinone IIA; monocrotaline; signaling pathway